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Endothelial GLP-1 (Glucagon-Like Peptide-1) 
Receptor Mediates Cardiovascular Protection 
by Liraglutide In Mice With Experimental Arterial 
Hypertension
Johanna Helmstädter, Katie Frenis, Konstantina Filippou, Alexandra Grill, Mobin Dib, Sanela Kalinovic, Franziska Pawelke,  
Kamil Kus, Swenja Kröller-Schön, Matthias Oelze, Stefan Chlopicki, Detlef Schuppan, Philip Wenzel, Wolfram Ruf,  
Daniel J. Drucker, Thomas Münzel, Andreas Daiber, Sebastian Steven
OBJECTIVE: Cardiovascular outcome trials demonstrated that GLP-1 (glucagon-like peptide-1) analogs including liraglutide 
reduce the risk of cardiovascular events in type 2 diabetes mellitus. Whether GLP-1 analogs reduce the risk for atherosclerosis 
independent of glycemic control is challenging to elucidate as the GLP-1R (GLP-1 receptor) is expressed on different cell 
types, including endothelial and immune cells.
APPROACH AND RESULTS: Here, we reveal the cardio- and vasoprotective mechanism of the GLP-1 analog liraglutide at the 
cellular level in a murine, nondiabetic model of arterial hypertension. Wild-type (C57BL/6J), global (Glp1r−/−), as well 
as endothelial (Glp1rflox/floxxCdh5cre) and myeloid cell–specific knockout mice (Glp1rflox/floxxLysMcre) of the GLP-1R were 
studied, and arterial hypertension was induced by angiotensin II. Liraglutide treatment normalized blood pressure, cardiac 
hypertrophy, vascular fibrosis, endothelial dysfunction, oxidative stress, and vascular inflammation in a GLP-1R–dependent 
manner. Mechanistically, liraglutide reduced leukocyte rolling on the endothelium and infiltration of myeloid Ly6G−Ly6C+ 
and Ly6G+Ly6C+ cells into the vascular wall. As a consequence, liraglutide prevented vascular oxidative stress, reduced 
S-glutathionylation as a marker of eNOS (endothelial NO synthase) uncoupling, and increased NO bioavailability. Importantly, 
all of these beneficial cardiovascular effects of liraglutide persisted in myeloid cell GLP-1R-deficient (Glp1rflox/floxxLysMcre) 
mice but were abolished in global (Glp1r−/−) and endothelial cell–specific (Glp1rflox/floxxCdh5cre) GLP-1R knockout mice.
CONCLUSIONS: GLP-1R activation attenuates cardiovascular complications of arterial hypertension by reduction of vascular 
inflammation through selective actions requiring the endothelial but not the myeloid cell GLP-1R.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: angiotensin II ◼ glucagon-like peptide-1 receptor ◼ hypertension ◼ inflammation ◼ liraglutide ◼ oxidative stress
Arterial hypertension is one of the leading risk factors for atherosclerosis, which culminates in thrombo-embolic events such as myocardial infarction or 
stroke and thereby represents a leading cause of global 
mortality and morbidity with severe disability.1 Basic 
research and clinical trials provide substantial evidence 
for a key role of inflammation in arterial hyperten-
sion.2,3 In experimental studies, depletion of inflamma-
tory cells in ATII (angiotensin II)-infused mice prevented 
increased blood pressure and endothelial dysfunction.4,5 
Furthermore, the CANTOS trial (Canakinumab Antiin-
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anti-inflammatory treatment of cardiovascular disease 
with the monoclonal antibody canakinumab, targeting 
IL (interleukin)-1β, reduces major adverse cardiovascu-
lar events by 15% compared with placebo in patients 
with atherosclerotic cardiovascular disease.3 Thus, anti-
inflammatory therapy has the potential to significantly 
lower rates of recurrent cardiovascular events.
GLP-1 (glucagon-like peptide-1) is a peptide hor-
mone with known anti-inflammatory properties that was 
first discovered as a regulator of insulin release from β-
cells in the pancreas, and synthetic analogs of GLP-1 are 
used for the treatment of type 2 diabetes mellitus. Clinical 
trials of GLP-1 analogs were designed to test the cardio-
vascular safety in patients with diabetes mellitus. Unex-
pectedly, long-acting GLP-1R (GLP-1 receptor) agonists 
reduced the risk of cardiovascular events in subjects with 
type 2 diabetes mellitus, with similar risk reduction (eg, 
LEADER trial [Liraglutide Effect and Action in Diabetes 
Evaluation of Cardiovascular Outcome Results] hazard 
ratio, 0.87 [95% CI 0.78–0.97] P=0.01) as observed for 
IL-1β blockade by canakinumab (hazard ratio, 0.85 [95% 
CI. 0.74–0.98] P=0.21).3,6,7 Other clinical trials investi-
gating the effects of GLP-1 on cardiovascular disease 
demonstrated cardiovascular protective effects after 
myocardial infarction,8 reduction of blood pressure,9 and 
an improvement of endothelial dysfunction.10 Although 
the mechanisms are not fully understood, reduction of 
inflammation has been suggested to play an important 
role for cardiovascular protection by GLP-1 analogs.
Multiple experimental studies have shown that 
native GLP-1 and pharmacological GLP-1R agonists 
reduce cardiac and vascular inflammation (for review, 
see Drucker et al11). Our group demonstrated that the 
GLP-1 analog liraglutide improves survival in lipopoly-
saccharide-induced endotoxemia by improving vascular 
function and reducing systemic and vascular inflamma-
tion12 and that these protective effects are lost in global 
Glp1r−/− mice with sepsis.13 In cell culture experiments, 
Krasner et al14 showed that liraglutide lowers the induc-
tion of VCAM-1 (vascular cell adhesion molecule-1) and 
E-cadherin by lipopolysaccharide and reduces adhesion 
of THP-1 (Tohoku hospital pediatrics-1) monocytes to 
human aortic endothelial cells. Furthermore, animal stud-
ies revealed that GLP-1R agonists, including native 
GLP-1, exendin-4, and liraglutide, attenuate the devel-
opment of atherosclerosis in murine models.11 GLP-1R 
agonists are known to reduce white blood cell infiltration 
and adhesion to the vascular wall in mouse models of 
atherosclerosis and cardiac dysfunction.15–17 However, 
the precise mechanism(s) mediating the cardiovascular 
protective effects of GLP-1 remains poorly understood, 
and their elucidation is complicated by the fact that the 
canonical GLP-1R is expressed on several cell types in 
the vasculature, heart, and on immune cells.15,18,19 Addi-
tionally, analysis of GLP-1R expression is complicated by 
poor specificity and sensitivity of many antibodies (for 
review see Pujadas et al20). Previous studies reported 
an essential role of myeloid cells4 and endothelial acti-
vation together with eNOS (endothelial NO synthase) 
dysfunction for the pathogenesis of hypertension.21 To 
pursue the underlying mechanisms, we have now studied 
genetic mouse models inactivating the Glp1r in myeloid 
or endothelial cell lineages.
Here, we show that liraglutide confers antioxidant and 
anti-inflammatory effects through mechanisms requir-
ing the endothelial GLP-1R. These findings may have 
relevance for ongoing efforts directed at understanding 
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1R knockout
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IL interleukin
iNOS inducible NO synthase
LEADER  Liraglutide Effect and Action in Dia-
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TNF-α tumor necrosis factor alpha
VCAM-1 vascular cell adhesion molecule-1
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Highlights
• In the present study, we reveal in a mouse model of 
arterial hypertension:
• that GLP-1 (glucagon-like peptide-1) analogs 
reduce blood pressure and protect endothelial func-
tion independent of glucose control;
• that GLP-1 analogs avoid uncoupling of eNOS 
(endothelial NO synthase) by reduction of vascular 
inflammation and oxidative stress;
• that these protective effects by GLP-1 analogs 
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clinical observations linking GLP-1R agonists to reduc-
tion of major adverse cardiovascular events.
MATERIALS AND METHODS
The authors declare that all supporting data are available within 
the article and its online-only Data Supplement.
Animals and In Vivo Treatment
All animals were treated in accordance with the Guide for 
the Care and Use of Laboratory Animals as adopted by the 
US National Institutes of Health and approval was granted 
by the Ethics Committee of the University Hospital Mainz 
and the Landesuntersuchungsamt Rheinland-Pfalz (Koblenz, 
Germany; permit number: 23 177-07/G 17-1-050). The stud-
ies were performed in male C57BL/6J, global Glp1r−/−,22 and 
endothelial (Glp1rflox/floxxCdh5cre, Glp1r ec−/−) as well as myelo-
monocytic (Glp1rflox/floxxLysMcre, Glp1r my−/−) cell–specific 
GLP-1R knockout mice (8–12 weeks old).23,24 According 
to Payne et al,23 a nonspecific cre recombinase activity has 
been noted in hematopoietic cells for the Cdh5-cre alleles. In 
the recent study, unintended deletion of the GLP-1R in Glp1r 
ec−/− mice other than endothelial cells was excluded by evalu-
ation of Glp1r mRNA in mouse white blood cells (Figure IIIF 
in the online-only Data Supplement). Animals were housed 
under a 12-hour light/dark cycle in the institutional animal 
facility with free access to standard diet and water. Effects 
of sexual hormones on vascular function are known.25 To 
exclude the latter effects in the present study, experiments 
were performed in male mice only. For detailed description, 
see online-only Data Supplement.
Detection of Oxidative Stress
Oxidative stress was detected in whole blood, heart, and vas-
cular tissue.26,27 For detailed description, see online-only Data 
Supplement.
Noninvasive Blood Pressure Recordings
Noninvasive blood pressure recording was performed by tail-
cuff to determine systolic blood pressure with a Coda Monitor 
System (Kent Scientific), which has been validated against 
telemetry monitoring.28 For detailed description, see online-
only Data Supplement.
S-Glutathionylation of eNOS and Western 
Blotting
eNOS was immunoprecipitated, and the precipitate was sub-
sequently immunoblotted for S-glutathionylation.29 For detailed 
description, see online-only Data Supplement.
Electron Paramagnetic Resonance 
Spectroscopy
Electron paramagnetic resonance spectroscopy was used to 
assess aortic NO synthesis/bioavailability using colloid Fe(II)-
diethyldithiocarbamate (Fe[DETC]2) as spin trap.
30 For detailed 
description, see online-only Data Supplement.
Determination of Nitrate and Nitrite
Nitrite and nitrate were measured by ENO-20 NOx analyzer 
(Eicom Corporation, Tokyo, Japan), based on the liquid chromatog-
raphy method with postcolumn derivatization with Griess reagent.31 
For detailed description, see online-only Data Supplement.
Intravital Fluorescence Microscopy
A real-time imaging software (NIS Elements, Nikon) was used 
for image acquisition and analysis. Cell recruitment was quanti-
fied in 6 fields of view (100μm×150μm) per femoral vein.32 For 
detailed description, see online-only Data Supplement.
Isometric Tension Recordings
For vascular reactivity studies, 4 mm thoracic aortic rings free of 
perivascular fat were mounted on force transducers in organ bath 
chambers and preconstricted with prostaglandin F2α (2 μM) to reach 
≈80% of the maximal tone induced by KCl bolus. Concentration-
relaxation curves were recorded in response to the endothelium-
dependent vasodilator acetylcholine (1 nM–3.3 μM).33
Reverse Transcription Polymerase Chain 
Reaction
The acid guanidinium thiocyanate-phenol-chloroform extrac-
tion method was used for RNA isolation.34 For detailed descrip-
tion see online-only Data Supplement.
Statistics
Data are expressed as means±SEM. Statistical calculations 
were performed with GraphPad Prism 7 (GraphPad Software, 
Inc). The unpaired Student t test was used after testing for 
normality and equal variance (Shapiro-Wilk test) to compare 
2 groups. One-way ANOVA and Bonferroni or Tukey post hoc 
test were used to compare multiple groups if the data followed 
a normal distribution, otherwise nonparametric Kruskal-Wallis 
and Dunn post hoc tests were used. Two-way ANOVA (with 
Bonferroni correction for comparison of multiple means) was 
used for comparisons of vasodilator potency and efficacy in 
response to the endothelium-dependent vasodilator acetylcho-
line. A limitation of the study is a reduced sample size in some 
experiments in which only 3 to 4 animals were used. P<0.05 
were considered statistically significant and marked by aster-
isks (*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001).
RESULTS
Liraglutide Improves Blood Pressure and 
Cardiac Hypertrophy in ATII-Induced Arterial 
Hypertension Independent of Glucose/Insulin 
Modulation
Chronic ATII infusion in C57BL/6J mice increased systolic 
blood pressure associated with development of cardiac 
hypertrophy. These effects of ATII infusion were com-
pletely normalized by administration of the GLP-1 analog 
liraglutide (Figure 1A through 1C). Liraglutide led to a sig-
nificant reduction in body weight after 7 days of treatment, 
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on body weight (Figure 1D). Neither ATII infusion nor lira-
glutide treatment had any significant effect on glucose 
homeostasis, as assessed by unaltered blood glucose and 
plasma insulin levels after an oral glucose tolerance test 
(Figure 1E and 1F, Figure IH and II in the online-only Data 
Supplement). Expression of Glp1r mRNA in aorta was not 
affected by ATII but was significantly elevated in response 
to liraglutide treatment (Figure IA in the online-only Data 
Supplement). Thus, liraglutide reduces blood pressure 
without impacting glucose homeostasis in nondiabetic 
mice with ATII-induced arterial hypertension, leading to 
amelioration of cardiac hypertrophy.
Liraglutide Reduces Cardiac and Whole 
Blood Oxidative Stress by Suppression of 
Inflammation and NADPH Oxidase Activity in 
ATII-Induced Arterial Hypertension
Hypertensive mice had significantly higher levels of reac-
tive oxygen species in whole blood and cardiac tissue, 
accompanied by elevated levels of 3-NT (3-nitrotyrosine) 
positive proteins in the heart, all of which were reduced by 
liraglutide treatment (Figure 2A through 2C). In addition, 
liraglutide significantly decreased ATII-induced oxidative 
stress in cardiac tissue caused by an increase of Nox 
(NADPH oxidase) activity (Figure 2D), reduced elevated 
levels of ADMA (asymmetrical dimethylarginine) known 
to promote dysregulation of the eNOS (Figure 2E), and 
attenuated F4/80 expression in cardiac tissue as an 
indicator for infiltration of immune cells into the heart 
(Figure 2F). Thus, liraglutide reduces cardiac oxidative 
stress in ATII-induced hypertensive heart disease.
Liraglutide Improves ATII-Induced Endothelial 
Dysfunction and Vascular Fibrosis by Reduction 
of Vascular Oxidative Stress and Recoupling of 
eNOS
ATII-infused mice exhibited impaired endothelial function, 
and Sirius red staining revealed significant vascular fibrosis, 
Figure 1. Liraglutide (Lira) improves blood pressure and cardiac hypertrophy in ATII (angiotensin II)-induced arterial 
hypertension independent of glucose/insulin modulation.  
A, In wild-type mice (C57BL/6J), systolic blood pressure was measured by noninvasive blood pressure recording on day 6 after beginning of ATII 
infusion. B, Heart/body weight ratio is shown next to (C) representative pictures of mouse hearts to demonstrate ATII-induced cardiac hypertrophy. 
D, Animals were weighed before and after 7 d of treatment to determine Δbody weight. E, Fasting blood glucose levels and (F) insulin levels after 
oral glucose tolerance testing were evaluated in whole blood/plasma after 7 d of treatment. One-way ANOVA and Bonferroni multiple comparison 
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a contributor to vascular stiffness. Treatment with liraglu-
tide reduced the development of these adverse vascular 
effects in ATII-treated mice (Figure 3A and 3D), whereas 
liraglutide treatment had no effect on vascular function in 
nonhypertensive animals (Figure IB in the online-only Data 
Supplement). ATII-infused mice showed eNOS uncoupling 
as revealed by a marked increase in S-glutathionylation 
of the enzyme and further supported by L-NAME (L-NG-
nitroarginine methyl ester) inhibitable endothelial dihydro-
ethidium staining (Figure 3B and 3C), consistent with the 
extent of endothelial dysfunction (Figure 3A) and impaired 
NO bioavailability (Figure 3E). These adverse effects of 
ATII infusion were all normalized by liraglutide treatment 
(Figure 3A through 3E). eNOS protein expression was not 
different between the groups (Figure IG in the online-only 
Data Supplement). Plasma levels of nitrate (NO3
−) were 
increased in hypertensive mice, indicative of pronounced 
oxidative break-down of NO and/or iNOS (inducible NO 
synthase) activity, which was further supported by increased 
mRNA expression of Nox2 and iNOS (or Nos2) in the aorta 
of ATII-infused mice (Figure 3F through 3H). Liraglutide 
administration significantly reduced the inflammatory bur-
den reflected by lowered Nox2 and Nos2 mRNA levels 
in aorta and attenuated nitrate plasma levels (Figure 3F 
through 3H). Thus, the GLP-1 analog liraglutide displays 
antioxidant and anti-inflammatory properties that help to 
prevent eNOS uncoupling, resulting in higher NO bioavail-
ability and vascular protection in arterial hypertension.
Liraglutide Ameliorates ATII-Induced 
Inflammation of the Vasculature by Prevention 
of Ly6G−Ly6C+- and Ly6G+ Ly6C+ Cell Infiltration 
to the Vessel Wall
Intravital microscopy visualized a trend of increased roll-
ing of leukocytes at the inner vascular wall in ATII-infused 
mice. Liraglutide administration significantly suppressed 
Figure 2. Liraglutide (Lira) reduces cardiac and whole blood oxidative stress by suppression of inflammation and NADPH 
oxidase activity in ATII (angiotensin II)-induced arterial hypertension.  
A, In wild-type mice (C57BL/6J), whole blood oxidative burst was determined by chemiluminescence (8-amino-5-chloro-7-phenylpyrido[3,4-d]
pyridazine-1,4-(2H,3H)dione sodium salt [L-012]) after zymosan A stimulation. B and C, Cardiac formation of reactive oxygen species was 
visualized by dihydroethidium (DHE) staining in cryosections of the left ventricle and dot blot analysis of cardiac tissue (left ventricle) using a 
specific antibody against 3-nitrotyrosine (3-NT). Representative photomicrographs (red fluorescence, superoxide formation) and representative 
dot blot images are shown beside the densitometric analysis. D, The activity of NADPH oxidase in isolated membranous fraction of cardiac 
tissue was examined by lucigenin-enhanced chemiluminescence. E, Asymmetrical dimethylarginine (ADMA) as an indicator for eNOS 
(endothelial NO synthase) dysfunction and (F) F4/80 levels as a readout for inflammation were determined by dot blot analysis in cardiac 
tissue. Representative dot blot images are shown beside the densitometric analysis. One-way ANOVA and Bonferroni multiple comparison 
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rolling of leukocytes in arterial hypertension (Figure 4A). 
Representative videos of intravital microscopy are avail-
able in the online-only Data Supplement. In support of 
an enhanced inflammatory phenotype in the aorta of 
hypertensive mice, nuclear factor κb (NF-κb; Figure 4B), 
tumor necrosis factor alpha (Tnfa) mRNA, and IL-1β pro-
tein expression, as well as transforming growth factor 
beta (Tgfb) and interferon gamma (Infg) mRNA expres-
sion (Figure IC through IF in the online-only Data Sup-
plement) were markedly upregulated upon ATII infusion. 
Furthermore, mRNA transcripts corresponding to Vcam1, 
intercellular adhesion molecule-1 (Icam1) and Selp, 
encoding adhesion molecules (VCAM-1, ICAM-1 and 
P-selectin) and known downstream targets of NF-κb, 
were strongly upregulated in the aortas of ATII-infused 
mice (Figure 4C through 4E). This proinflammatory cas-
cade responsible for leukocyte adhesion and migration 
was mitigated by liraglutide treatment (Figure 4B through 
4E, Figure IC through IF in the online-only Data Supple-
ment). Immunohistochemical staining of blood vessels 
Figure 3. Liraglutide (Lira) improves ATII (angiotensin II)-induced endothelial dysfunction and vascular fibrosis by recoupling of 
eNOS (endothelial NO synthase) and reduction of vascular oxidative stress.  
A, In wild-type mice (C57BL/6J), vascular function was evaluated by endothelium (E)-dependent (acetylcholine [ACh]) relaxation of aortic rings 
(isometric tension studies). Two-way ANOVA and Bonferroni multiple comparison test; N=16–28 animals per group. B, S-glutathionylation 
of eNOS as a readout for uncoupling of the enzyme was measured by using a specific glutathione antibody (GSH) after immunoprecipitation 
of eNOS. Representative Western blot images are shown below the densitometric analysis. C, The specific NOS-inhibitor L-NAME (L-NG-
nitroarginine methyl ester) was used in aortic cryosections stained with dihydroethidium (DHE) to detect reactive oxygen species (ROS) and to 
uncover eNOS uncoupling. Representative photomicrographs are shown below the densitometric analysis. Green, laminae (autofluorescence); 
red fluorescence, superoxide formation. D, Representative (out of 3–4) Sirius red stainings of aorta are shown to demonstrate vascular fibrosis. 
E, Electron paramagnetic resonance spectroscopy revealed NO levels in aorta. Representative electron paramagnetic resonance spectroscopy 
(EPR) spectra showing the resulting iron-nitrosyl triplet signal are shown besides the quantification bar graph. F, High-performance liquid 
chromatography (HPLC) was used to detect nitrate (NO3
−) in plasma. Representative chromatograms are shown beside the quantification bar 
graph. G and H, NADPH oxidase 2 (Nox2) and inducible NO synthase (iNOS/Nos2) mRNA expression was measured by quantitative reverse 
transcription polymerase chain reaction in aortic tissue. One-way ANOVA and Bonferroni multiple comparison test; N=4 (B), 8 without and 3 
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revealed high expression of Ly6B.2 as an indicator for 
vascular inflammation in ATII-infused mice, which was 
normalized by liraglutide treatment (Figure 4F). Using 
flow cytometry, we identified specific subsets of immune 
cells, namely Ly6G−Ly6C+ inflammatory monocytes and 
Ly6G+Ly6C+ neutrophils, that infiltrated into the vascu-
lar wall of hypertensive animals, findings attenuated by 
liraglutide administration (Figures 4G and 4H). Thus, lira-
glutide ameliorates ATII-induced rolling and infiltration of 
leukocytes by downregulation of central proinflammatory 
mediators (NF-κb, TNF-α, and IL-1β) with concomitant 
reduced expression of adhesion molecules (VCAM-1, 
ICAM-1, and P-selectin).
Canonical GLP-1R Expressed on Endothelial 
Cells, Not on Myeloid Cells, Is Essential for 
Cardiovascular Protection by Liraglutide.
Global Glp1r−/− mice exhibited impaired endothelial func-
tion compared to C57BL/6J mice, which was further 
deteriorated by ATII infusion; treatment with liraglutide did 
Figure 4. Liraglutide (Lira) ameliorates ATII (angiotensin II)-induced inflammation of the vasculature by prevention of 
Ly6G−Ly6C+- and Ly6G+ Ly6C+ cell infiltration to the vascular wall.  
A, In wild-type mice (C57BL/6J), rolling of leukocytes at the vascular wall (V. femoralis) was quantified by intravital microscopy. Nucleated cells 
were visualized by staining with acridine orange. Representative images at day 7 are shown below the quantification bar graph. Representative 
videos of intravital microscopy experiments are available in the online-only Data Supplement. B–E, mRNA expression of genes encoding for 
nuclear factor-κb (NF-κb) and adhesion molecules vascular cell adhesion molecule-1 (Vcam1), intercellular adhesion molecule-1 (Icam1), and 
P-selectin (Selp) in aorta were measured by quantitative reverse transcription polymerase chain reaction. F–H, Vascular inflammation was 
further characterized by immunohistochemistry and flow cytometry of aortic tissue. Representative pictures of 3–4 independent aortic Ly6 
(Ly6B.2) immunohistochemical stainings (F; for IgG isotype control see Figure V in the online-only Data Supplement) and flow cytometry of 
Ly6G−Ly6C+ inflammatory monocytes and Ly6G+Ly6C+ neutrophils in aortic cell suspensions (G and H) are shown. Representative original 
plots of Ly6G−Ly6C+ and Ly6G+Ly6C+ cells are shown beside the quantification bar graph (for gating strategy, see Figure IV in the online-only 
Data Supplement). One-way ANOVA and Bonferroni multiple comparison test; N=6 (A), 3 (B–E) and 12-14 (G and H) animals per group. Data 
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not improve acetylcholine-dependent vasodilation in the 
absence of a functional canonical GLP-1R (Figure 5A). 
Similarly, liraglutide did not reduce vascular oxidative 
stress in ATII-infused Glp1r−/− mice (Figure 5B). Fur-
thermore, liraglutide failed to normalize and even dete-
riorated levels of aortic Nox2, Nos2, and Tnfa mRNA as 
well as cardiac Nox2 activity in ATII-infused Glp1r−/− mice 
(Figures 5C through 5F). Collectively, these findings sug-
gest that the cardiovascular protection seen in C57BL/6J 
mice is mediated via canonical GLP-1R activation.
To better define the cellular target of vascular-pro-
tective liraglutide signaling through GLP-1R, we gener-
ated endothelial cell–specific (Glp1r ec−/−) and myeloid 
cell–specific (Glp1r my−/−) GLP-1R knock-out mice. 
Figure 5. The canonical GLP-1 (glucagon-like peptide-1) receptor is essential for vascular protection by liraglutide (Lira) in mice 
with arterial hypertension.  
A, In global GLP-1 receptor knockout mice (Glp1r−/−), vascular function was evaluated by endothelium (E)-dependent (acetylcholine [ACh]) 
relaxation of aortic rings (isometric tension studies). Two-way ANOVA and Bonferroni multiple comparison test; N=8–10 animals per group. 
B, Aortic cryosections stained with dihydroethidium (DHE) were used to detect reactive oxygen species in the vascular wall. Representative 
photomicrographs are shown below the densitometric analysis. Green, laminae (autofluorescence); red fluorescence, superoxide formation. C, 
Aortic mRNA expression of NADPH oxidase 2 (Nox2) was evaluated by quantitative reverse transcription polymerase chain reaction (rtPCR). 
D, Activity of all NADPH oxidase isoforms was measured by chemiluminescence (lucigenin) in cardiac membranous fraction. E and F, Inducible 
NO synthase (iNOS/Nos2) and Tnfa mRNA expression were measured by quantitative rtPCR in aortic tissue. One-way ANOVA and Bonferroni 
multiple comparison test; N=10–11 (B), 3 (C), 6 (D) and 3 (E and F) animals per group. Data are means±SEM. A indicates adventitia; ATII, 
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Figure 6. The canonical GLP-1 (glucagon-like peptide-1) receptor expressed on myeloid cells (LysM+) is not responsible for 
cardiovascular protection by liraglutide (Lira).  
A, In myeloid cell (LysM+)-specific GLP-1 receptor knockout mice (Glp1rflox/floxxLysMcre, Glp1r my−/−), mRNA expression of the Glp1r was 
measured in bone marrow–derived macrophages (BMDM) and expression levels are shown in relation to the background strain (LysMcre mice). 
Student t test; N=3 animals per group. B, Vascular function was evaluated by endothelium-dependent (acetylcholine [ACh]) relaxation of aortic 
rings (isometric tension studies). Two-way ANOVA and Bonferroni multiple comparison test; N=16–22 animals per group. C, Representative 
(out of 3–4) Sirius red staining of aortic sections to assess vascular fibrosis. D and E, Flow cytometry of aortic cell suspensions identified 
Ly6G−Ly6C+ inflammatory monocytes and Ly6G+Ly6C+ neutrophils inside the vascular wall. Representative original plots of Ly6G−Ly6C+ and 
Ly6G+Ly6C+ cells are shown beside the quantification bar graph (for gating strategy, see Figure IV in the online-only Data Supplement). One-
way ANOVA and Bonferroni multiple comparison test; N=5–9 animals per group. Data are means±SEM. ATII indicates angiotensin II; FITC, 
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Figure 7. The canonical GLP-1 (glucagon-like peptide-1) receptor expressed on endothelial cells is essential for 
cardiovascular protection by liraglutide (Lira).  
A, In endothelial cell–specific GLP-1 receptor knockout mice (Glp1rflox/floxxCdh5cre, Glp1r ec−/−), mRNA expression of the Glp1r was 
measured in isolated mouse lung endothelial cells (MLECs) and expression levels are shown in relation to the background strain 
(Cdh5cre mice). Student t test; N=4 animals per group. B, Vascular function was evaluated by endothelium-dependent (acetylcholine 
[ACh]) relaxation of aortic rings (isometric tension studies). Two-way ANOVA and Bonferroni multiple comparison test; N=20–30 
animals per group. C, Systolic blood pressure in mice was determined by noninvasive blood pressure recording on day 6 of ATII 
(angiotensin II) infusion. D, Representative (out of 3–4) Sirius red staining of aortas reveal vascular fibrosis. E, NADPH oxidase 2 
(Nox2) mRNA expression was measured by quantitative reverse transcription polymerase chain reaction in aortic tissue. F, high-
performance liquid chromatography (HPLC) was used to detect nitrate (NO3
−) in plasma. Representative chromatograms are shown 
below the quantification bar graph. G and H, Flow cytometry of aortic tissue identified Ly6G−Ly6C+ inflammatory monocytes and 
Ly6G+Ly6C+ neutrophils inside the vascular wall. Representative original plots of Ly6G−Ly6C+ and Ly6G+Ly6C+ cells are shown beside 
the quantification bar graph (for gating strategy, see Figure IV in the online-only Data Supplement). One-way ANOVA and Bonferroni 
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Glp1r mRNA in bone marrow–derived macrophages of 
myeloid-specific knockout mice (Glp1r my−/−) was not 
detectable compared to the background strain (LysMcre 
mice; Figure 6A). Moreover, ATII infusion and liraglu-
tide treatment did not alter nonfasting blood glucose in 
Glp1r ec−/− and Glp1r my−/− mice (Figures IIA and IIIA in 
the online-only Data Supplement). However, liraglutide 
reduced body weight in both mouse strains (Figures IIB 
and IIIB in the online-only Data Supplement).
Given the demonstrated reduction of leukocyte infiltra-
tion by liraglutide treatment in the wild-type mice, we first 
analyzed the response to ATII infusion in Glp1r my−/− mice. 
Unlike findings in the global Glp1r−/−, ATII-induced vascular 
dysfunction was evident in Glp1r my−/− mice, and endothelial 
responsiveness was restored by liraglutide (Figure 6B). In 
addition, cardiac hypertrophy (Figure IIC in the online-only 
Data Supplement), vascular fibrosis (Figure 6C), and myeloid 
cell infiltration of the vessel wall induced by ATII infusion 
was markedly reduced by liraglutide treatment (Figure 6D 
and 6E). Hence, GLP-1R expression in myeloid cells is not 
required for the cardiovascular protective effect of liraglutide.
Mouse lung endothelial cells of Glp1r ec−/− (Glp1rflox/flox 
xCdh5cre) mice contained about 90% less Glp1r mRNA 
compared with the background strain (Cdh5cre mice), and 
a knockdown of Glp1r in white blood cells was ruled out 
(Figure 7A, Figure IIIF in the online-only Data Supple-
ment). In contrast to Glp1r my−/− mice, liraglutide failed 
to improve endothelial function (Figure 7B) or reduce 
blood pressure (Figure 7C) in hypertensive Glp1r ec−/− 
mice. Vascular fibrosis (Figure 7D) and cardiac hypertro-
phy (Figure IIIC in the online-only Data Supplement) was 
aggravated by ATII infusion and not significantly improved 
by liraglutide treatment in Glp1r ec−/− mice, in contrast 
to findings in Glp1r my−/− mice. Furthermore, liraglutide 
failed to prevent upregulation of Nox2, Vcam1, and Tnfa 
mRNA (Figure 7E and Figure IIID and IIIE in the online-
only Data Supplement) as well as higher nitrate levels 
indicative of oxidative NO break-down and iNOS activity 
(Figure 7F) in hypertensive Glp1r ec−/− mice. Associated 
with these signs of persistent endothelial dysfunction, the 
infiltration of Ly6G−Ly6C+ inflammatory monocytes and 
Ly6G+Ly6C+ neutrophils was not significantly reduced by 
liraglutide treatment of ATII-infused Glp1r ec−/− mice (Fig-
ure 7G and 7H). Thus, the cardiovascular protection of 
liraglutide in mice with ATII-induced vascular dysfunction 
is predominantly mediated via the endothelial GLP-1R.
DISCUSSION
Here, we show that the GLP-1 analog liraglutide prevents 
the adverse cardiovascular effects of ATII-induced arterial 
hypertension. Liraglutide exerts its cardiovascular protec-
tive actions through the GLP-1R and normalizes vascular 
inflammation, oxidative stress, endothelial function, blood 
pressure, and cardiac hypertrophy in this animal model of 
arterial hypertension. Mechanistically, GLP-1R activation by 
liraglutide attenuates vessel wall infiltration by Ly6G−Ly6C+ 
inflammatory monocytes and Ly6G+Ly6C+ neutrophils, 
which in turn lowers oxidative stress and prevents uncou-
pling of eNOS in hypertensive mice. NO bioavailability is 
thereby maintained, endothelium-mediated vasorelaxation 
is preserved, and vascular remodeling and fibrosis are pre-
vented. Consistent with the known actions of GLP-1, we 
found no effects of liraglutide on glycemia or insulin levels, 
supporting a glucose-independent mechanism. We identify 
that the canonical GLP-1R expressed on endothelial cells, 
but not on myeloid cells, is required for the cardiovascular 
protection by the GLP-1 analog liraglutide.
GLP-1R agonists lower blood pressure in preclinical 
studies and humans. One potential mechanism was pro-
posed by Kim et al19 who showed that GLP-1R activation 
by liraglutide promotes the secretion of ANP (atrial natri-
uretic peptide) with a subsequent increase of cGMP-medi-
ated vasorelaxation and urinary sodium secretion leading to 
reduction of blood pressure in ATII-infused mice. The effect 
was dependent on the canonical GLP-1R and absent in 
global GLP-1R knockout mice. With the present studies, we 
found a comparable blood pressure reduction by liraglutide, 
which resulted in a reduction of cardiac hypertrophy and 
reduced heart/body weight ratio (both parameters indica-
tive of hypertensive heart disease), which were associated 
with a reduction of body weight but independent of glucose-
lowering. Liraglutide also reduced systemic and cardiac 
oxidative stress and inflammation. Studies using a cardio-
myocyte-specific GLP-1R knockout strain (Glp1rCM−/−) 
found no relevant role for the GLP-1R expressed on car-
diomyocytes in ischemic cardiomyopathy,24 which excludes 
that direct liraglutide effects on cardiomyocytes are respon-
sible for the cardioprotective effects. Thus, improvements of 
cardiac hypertrophy, cardiac oxidative stress, and inflamma-
tion likely result from blood pressure lowering effects and 
prevention of infiltration of immune cells by liraglutide. The 
blood pressure reduction by liraglutide was consistent with 
previous data19 but clearly of greater magnitude compared 
with human studies in which a blood pressure reduction of 
2 to 4 mm Hg is reported.35 The latter represents a limitation 
of the present study with respect to translation of our animal 
data and their clinical relevance.
Vascular inflammation is a crucial component in the 
development of arterial hypertension2 with sequential 
steps of inflammatory cell infiltration into the vascular 
wall, resulting in high levels of vascular oxidative stress 
and eNOS uncoupling and finally atherosclerosis.2,4,5,36–38 
GLP-1R activation on endothelial cells prevented these 
effects and improved vascular relaxation and NO bioavail-
ability in ATII-infused mice. Mechanistically, liraglutide 
suppressed an inflammatory cascade involving NF-κb 
and downregulated mRNA encoding vascular adhesion 
molecules VCAM-1, ICAM-1, and P-selectin in the arter-
ies, which explains the observed reduction in leukocyte 
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In a selective ablation model of lysozyme M-positive 
(LysM+) myelomonocytic cells, it has been shown that 
infiltrating proinflammatory monocytes and macrophages 
cause vascular oxidative stress and mediate ATII-induced 
vascular dysfunction.4 Consistent with these findings, 
reduced leukocyte infiltration in liraglutide-treated ani-
mals was associated with attenuated vascular reactive 
oxygen species production, restoration of the function of 
eNOS and suppression of Nos2/Nox2 mRNA expres-
sion. Under conditions of high oxidative stress, eNOS 
uncouples and converts into a source of reactive oxygen 
species, which is specifically detectable by reduced aortic 
NO bioavailability, eNOS S-glutathionylation, and eNOS-
dependent reactive oxygen species formation by using 
the selective NOS-inhibitor L-NAME in dihydroethidium 
cryosections.36,37 In contrast, increased iNOS activity was 
reflected by higher plasma nitrate levels, and both eNOS 
uncoupling as well as iNOS overactivation were linked 
in the setting of hypertension, as also previously dem-
onstrated for the ATII hypertension model.39 Liraglutide 
treatment interrupted this detrimental cascade in hyper-
tensive mice by prevention of leukocyte influx and vas-
cular inflammation.
Our data are in agreement with cell culture experi-
ments of Hattori et al40 demonstrating that liraglutide 
causes a dose-dependent increase of NO release in 
human umbilical vein endothelial cells via eNOS activa-
tion and downregulation of NFKB1, TNFA, VCAM1, and 
ICAM1 mRNA expression. Similar observations have 
been made in ApoE−/− mice treated with GLP-1 analog 
for 28 days, where exendin-4 reduced numbers of Mac-
2+ cells adhering to the endothelium and decreased lev-
els of Vcam1 and Icam1 mRNA.15 Similar evidence for 
a mechanistic involvement of the GLP-1R was demon-
strated using the GLP-1R antagonist exendin (9-39) to 
diminish liraglutide’s protective effect in atherosclerosis-
prone ApoE−/− mice.41
Anti-inflammatory effects of GLP-1 analogs are 
well established.11 Nevertheless, it still remains unclear 
whether GLP-1R agonists modify immune cell function 
through direct effects on immune cells or indirect mecha-
nisms (eg, suppression of endothelial cell activation) and 
whether these effects require the canonical GLP-1R. 
Immunoreactive GLP-1R protein and Glp1r mRNA tran-
scripts have been detected in murine monocytes and 
macrophages, but due to low sensitivity and specificity 
of GLP-1R antibodies, the precise cellular and tissue 
expression of the immune GLP-1R remains uncertain.42,43 
Endothelial cells also express the canonical GLP-1R; 
however, the importance of the endothelial GLP-1R for 
the cardiovascular protection by GLP-1R agonists has 
been unexplored.44 Nevertheless, multiple studies have 
demonstrated effects of GLP-1 analogs on endothelial 
cells and vascular function ex vivo and in vivo in mice and 
humans (for review see Drucker et al11). GLP-1R agonists 
are thought to exert cardiovascular protection dependent 
on the known GLP-1R. However, GLP-1(9-36)amide, 
generated by DPP-4-mediated cleavage of native GLP-
1, exerts cardioprotective actions in the ischemic mouse 
heart. Moreover, GLP-1(9-36) also exerts direct vasodila-
tory actions on murine blood vessels and induces vaso-
dilation in mesenteric vessels.45 These actions persisted 
in blood vessels of Glp1r−/− mice. Hence, we cannot fully 
exclude a potential contribution of GLP-1R independent 
effects of liraglutide and its metabolites,11 which repre-
sents a limitation of our present study.
Here, we demonstrated that the canonical GLP-1R 
expressed on endothelial cells, but not on myeloid cells, is 
required to improve endothelial dysfunction by reduction 
of vascular inflammation and oxidative stress in a murine 
model of arterial hypertension. Glp1r−/− mice exhibit 
endothelial dysfunction, which was only modestly exacer-
bated by ATII, suggesting a role of the endogenous GLP-
1R system in vascular function. The latter hypothesis is 
supported by a recent report by He et al46 who demon-
strated that increased endogenous GLP-1 bioavailability 
protects against atherosclerosis. Importantly, liraglutide 
failed to normalize endothelial function, vascular oxida-
tive stress, cardiac Nox activity, and mRNA expression 
of proinflammatory genes (Nox2, Nos2, Tnfa) in hyper-
tensive Glp1r−/− mice, clearly highlighting the essential 
role of GLP-1R signaling for cardiovascular protection 
by GLP-1 analogs. However, blood pressure and cardiac 
hypertrophy trended lower in liraglutide-treated Glp1r 
ec−/− mice, consistent with previous findings in mice 
invoking a role for ANP in the blood pressure reduction 
produced by GLP-1R agonists.19
In conclusion, clinical trials revealed that the GLP-1 
analog liraglutide and multiple structurally distinct GLP-
1R agonists improve cardiovascular outcomes through 
incompletely understood mechanisms, in which athero-
sclerosis might play an essential role.6 The present study 
provides evidence that liraglutide prevents endothelial 
dysfunction and lowers blood pressure in normoglycemic 
mice with experimental arterial hypertension, a major risk 
factor for atherosclerosis and subsequent cardiovascular 
disease. This was in concert with a reduction of vascular 
inflammation, and subsequent normalization of vascular 
oxidative stress. The GLP-1R expressed on endothelial, 
but not on myeloid cells, plays an indispensable role in 
the cardiovascular protection induced by liraglutide in 
mice with ATII-induced experimental hypertension. Given 
the major role of renin-angiotensin-aldosterone system 
activation for cardiovascular and renal complications 
observed in patients with diabetes mellitus,47 our present 
data obtained in a model of ATII-triggered hypertension 
may contribute to a better understanding of the cardio-
protective effects of liraglutide reported in clinical trials.6,7
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